Friday, February 13, 2009
FRIDAY, Feb. 13 (HealthDay News) -- Distant metastasis and general clinical treatment failure three years after prostate cancer treatment are effective surrogate endpoints for survival at 10 years, according to a report published in the Feb. 18 issue of the Journal of the National Cancer Institute.
Michael E. Ray, M.D., Ph.D., from Radiology Associates of Appleton in Appleton, Wis., and colleagues analyzed data from 1,521 patients with locally advanced prostate cancer who had been treated with neoadjuvant and concurrent androgen deprivation therapy with external beam radiation therapy for four months, then randomly assigned to no further treatment or 24 more months of androgen deprivation therapy.
Using data from the 1,364 patients who were alive after three years, the researchers found that distant metastasis and general clinical treatment failure at three years were effective surrogate endpoints for prostate cancer-specific survival at 10 years (based on Prentice's criteria). Using data from the 1,178 patients who were alive after five years, they found that the surrogate endpoints remained consistent with Prentice's criteria, even though prostate cancer-specific survival did not differ significantly between the two groups.
"The identification of a set of intermediate outcomes that collectively may be rather comprehensive concerning the pathways whereby a class of treatments could exert beneficial or harmful health effects may be a practical and useful aspect of the research agenda," Ross L. Prentice, Ph.D., from the Fred Hutchinson Cancer Research Center in Seattle, writes in an accompanying editorial.
One co-author of the study has ties to AstraZeneca.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.